Skip to content
Black Week: 20% off everything, code BLACK

Search

What are you looking for?

Type at least 2 characters to see suggestions.

Fat Loss and Metabolism Marek Wawrzyk

Retatrutide for obesity – action and effects of use

Retatrutide differs from other incretin analogues in one feature that should be stated at the outset: it acts on three receptors at once, rather than one or two.

Retatrutide for obesity - action and effects of use

Retatrutide differs from other incretin analogues in one feature that should be stated at the outset: it acts on three receptors at once, rather than one or two. Its regulatory status is also different. Unlike semaglutide and tirzepatide, retatrutide is not an approved medicine anywhere. It remains a compound under clinical investigation, with an ongoing development programme. This article explains the mechanism of triple agonism and what published phase 2 trials have shown. It provides no use protocols because no regulatory authority has established approved dosing for an unapproved compound.

All substances discussed in this article are research materials and are not intended for human consumption. Descriptions of their activity are based solely on laboratory research and experimental observations, not on clinical testing of the products offered by Pro-Body.

What is retatrutide and how does it work?

Retatrutide, development code LY3437943, is a synthetic peptide designed as an agonist of three receptors at the same time:

  • GLP-1 — the glucagon-like peptide-1 receptor; its activation increases glucose-dependent insulin secretion, suppresses glucagon secretion, slows gastric emptying and affects central appetite-regulation pathways,
  • GIP — the glucose-dependent insulinotropic polypeptide receptor, associated with the second major incretin,
  • the glucagon receptor — the feature that genuinely distinguishes this molecule.

The third target is particularly interesting because at first glance it appears contradictory. Glucagon raises blood glucose and acts as a physiological counter-regulator of insulin. Activating its receptor in a molecule designed for metabolic control seems counterintuitive until another aspect of its action is considered: glucagon-receptor agonism is associated with increased energy expenditure and mobilisation of liver fat. Concurrent GLP-1 and GIP agonism is intended to counterbalance the hyperglycaemic component.

In other words, the molecule combines an appetite-suppressing component, through GLP-1 and GIP, with an energy-expenditure component, through glucagon. A review of this class discusses the concept of triple agonism and its path from an idea to clinical investigation (Jakubowska et al., 2024, PMID 38356208).

Triple agonism: how it differs from semaglutide and tirzepatide

This distinction helps organise the entire class and is clearest in a direct comparison:

Molecule Receptors Regulatory status
Semaglutide GLP-1 Active ingredient in approved prescription medicines
Tirzepatide GLP-1 + GIP Active ingredient in approved prescription medicines
Retatrutide GLP-1 + GIP + glucagon Not approved; compound under clinical investigation

Adding each receptor changes the activity profile, but not through simple addition. Drucker reviewed GLP-1 physiology and its pharmacological implications (Drucker, 2018, PMID 29617641), (Drucker, 2022, PMID 34626851). The GIP component introduced with tirzepatide was characterised separately (Coskun et al., 2018, PMID 30473097). A separate article compares the mechanisms and registration-trial findings for semaglutide and tirzepatide: tirzepatide versus semaglutide.

The difference in regulatory status is more important here than the difference in mechanism. Semaglutide and tirzepatide have completed full regulatory pathways and are active ingredients in prescription medicines. Retatrutide has not completed that pathway. Phase 2 findings have been published, while phase 3 trials remain ongoing. Therefore, there is no approved retatrutide medicinal product, no approved dosing and no complete characterisation of its safety profile.

What phase 2 trials showed

The findings below come from manufacturer-funded clinical trials involving human participants. They are presented without dosing protocols because no regulatory authority has established approved dosing for an unapproved compound.

Trial in obesity

A randomised, double-blind, placebo-controlled phase 2 trial enrolled 338 adults with obesity or overweight plus a weight-related condition. Follow-up lasted 48 weeks, and the primary endpoint was percentage change in body weight at 24 weeks.

Across dose groups, mean body-weight change at 48 weeks ranged from −8.7% to −24.2%, compared with −2.1% in the placebo group. A reduction of at least 15% was recorded in 60–83% of participants in the higher-dose groups, compared with 2% in the placebo group (Jastreboff et al., 2023, PMID 37366315).

Two findings should be noted alongside these figures. First, the most common adverse events were gastrointestinal, dose-related and mostly mild to moderate. Second, and less often mentioned, a dose-dependent increase in heart rate was recorded. It peaked at approximately week 24 and then declined. This signal is consistent with the molecule’s glucagon component and is not part of the same profile as pure GLP-1 agonism.

Trial in type 2 diabetes

A second phase 2 trial enrolled 281 participants with type 2 diabetes at 42 centres in the United States. It used a double-blind, double-dummy design with placebo control and an active comparator, an approved GLP-1 agonist. The primary endpoint was change in glycated haemoglobin at 24 weeks (Rosenstock et al., 2023, PMID 37385280).

Correcting the participant count

A claim circulates that retatrutide has been tested in “more than 3,000 patients.” This is not supported by the published data. The two published phase 2 trials included a total of 619 participants, 338 and 281 respectively. This scale is typical of phase 2, whose purpose is dose selection and preliminary evaluation rather than confirmation of efficacy and safety in a large population. That is the role of phase 3, which remains ongoing for this molecule.

A crucial distinction: a clinically investigated compound and a research material

This is the most important section of the article. Three separate entities that are often conflated in informal discussion must be distinguished:

  1. Retatrutide in a clinical trial — a substance administered to participants at a research centre, with verified identity and purity, medical supervision, adverse-event monitoring, exclusion criteria and ethics oversight. All efficacy figures cited above describe this setting.
  2. An approved medicine — for retatrutide, this entity does not exist. There is no summary of product characteristics, patient leaflet, approved indication or approved dosing.
  3. A research-grade material — a reagent sold outside the pharmacy supply chain and intended for laboratory applications. It is neither a medicine nor the material administered within a clinical trial.

Efficacy data obtained in the first setting do not transfer to the third. This is not because the molecular name is necessarily different, but because a clinical trial measures a substance administered under defined conditions and within a complete supervision infrastructure. Outside those conditions, no trial team records adverse events, checks exclusion criteria or monitors parameters that received specific attention in the trial, such as the increase in heart rate.

The implication is unambiguous: incretin analogues in the research market are not “over-the-counter fat burners.” In retatrutide’s case, there is not even an approved medicinal counterpart against which such a research material could be compared.

What the studies do not show

An accurate account must also include what the published data do not cover.

  • Phase 3 data. Trials intended to establish efficacy and safety in large populations are ongoing. Until they are complete, claims of “confirmed safety” remain premature.
  • Long-term data. The longest published follow-up is 48 weeks. The multi-year profile of the molecule and what happens after discontinuation are not known.
  • Data in healthy people. Trial participants had obesity or type 2 diabetes. The findings do not describe effects in people without those diagnoses, including people training with the aim of reducing body fat.
  • Cardiovascular outcome data. Cardiovascular-event trials have been conducted for approved GLP-1 agonists (Lincoff et al., 2023, PMID 37952131). No comparable outcomes data are available for retatrutide, which is an important gap given the recorded increase in heart rate.

Regulatory status and anti-doping note

Retatrutide is not registered as a medicinal product in any jurisdiction, including the European Union and the United States. It is not a dietary supplement or food and is not eligible for health claims. Research materials containing this compound are not intended for human consumption.

WADA status. Retatrutide has no marketing authorisation in any country, so it falls under class S0 of the Prohibited List (non-approved substances) and is prohibited in sport at all times, in and out of competition. Class S0 covers any pharmacological substance not addressed by other sections of the List and not approved by any regulatory authority for human therapeutic use, even when the List does not name it. Approved GLP-1 analogues are treated differently: semaglutide and tirzepatide are not prohibited and are included in WADA’s Monitoring Program.

Anti-doping rules are not limited to professional athletes. In Poland, the Prohibited List is implemented through the Polish Anti-Doping Agency (POLADA), and amateur competitors participating in covered events may also be tested. An athlete registered in ADAMS should verify the current Prohibited List and Monitoring Program directly rather than relying on an article, including this one.

Frequently asked questions

How does retatrutide differ from semaglutide and tirzepatide?

It differs in the number of activated receptors and in regulatory status. Semaglutide acts at GLP-1, tirzepatide at GLP-1 and GIP, and retatrutide additionally at the glucagon receptor, which is associated with increased energy expenditure. The first two molecules are active ingredients in approved medicines; retatrutide is not approved anywhere.

Is retatrutide a medicine for obesity?

No. It is a compound under clinical investigation. It has no marketing authorisation, approved indication or summary of product characteristics. Phase 3 trials that will inform any future regulatory decision remain ongoing.

Has retatrutide been tested in more than 3,000 people?

No. The two published phase 2 trials included a total of 619 participants: 338 in the obesity trial and 281 in the type 2 diabetes trial. The claim of “more than 3,000” is not supported by the published data.

Which adverse events were reported in the trials?

The most common adverse events were gastrointestinal, dose-related and mostly mild to moderate. A dose-dependent increase in heart rate was also recorded, peaking at approximately week 24. This signal is consistent with the molecule’s glucagon component.

Why does this article provide no doses?

Retatrutide has not completed a regulatory process that establishes approved dosing. Values used in phase 2 trials served dose-selection research under medical supervision and do not constitute recommendations.

Summary

Retatrutide, development code LY3437943, is a peptide designed as a triple agonist of GLP-1, GIP and glucagon receptors. The glucagon component is its genuine distinguishing feature, combining appetite-related incretin signalling with increased energy expenditure. In a phase 2 trial of 338 participants with obesity, mean body-weight change at 48 weeks ranged from −8.7% to −24.2% across dose groups, compared with −2.1% with placebo; a dose-dependent increase in heart rate was also recorded. A second phase 2 trial included 281 participants with type 2 diabetes and used an active comparator. Together, these studies account for 619 participants, not more than 3,000 as is sometimes claimed. The most important distinction, however, is regulatory status: unlike semaglutide and tirzepatide, retatrutide is not an approved medicine in any jurisdiction, has no approved dosing and has not completed phase 3 trials. A research-grade material is also a different entity from a substance administered in a clinical trial, and efficacy data obtained under medical supervision do not transfer outside those conditions.

Product documentation

Research-material pages with batch analytical documentation: TRIPLE G — vial and TRIPLE G — pen. Other incretin analogues are listed in the category for peptides studied in lipid-metabolism models. These materials are intended exclusively for research use.

References

  1. Jastreboff AM, Kaplan LM, Frías JP, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. N Engl J Med. 2023;389(6):514-526. PMID: 37366315
  2. Rosenstock J, Frías J, Jastreboff AM, et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA. Lancet. 2023;402(10401):529-544. PMID: 37385280
  3. Jakubowska A, le Roux CW, Viljoen A. The Road towards Triple Agonists: Glucagon-Like Peptide 1, Glucose-Dependent Insulinotropic Polypeptide and Glucagon Receptor — An Update. Endocrinol Metab (Seoul). 2024;39(1):12-22. PMID: 38356208
  4. Sidrak WR, Kalra S, Kalhan A. Approved and Emerging Hormone-Based Anti-Obesity Medications: A Review Article. Indian J Endocrinol Metab. 2024;28(5):445-460. PMID: 39676791
  5. Coskun T, Sloop KW, Loghin C, et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept. Mol Metab. 2018;18:3-14. PMID: 30473097
  6. Drucker DJ. Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1. Cell Metab. 2018;27(4):740-756. PMID: 29617641
  7. Drucker DJ. GLP-1 physiology informs the pharmacotherapy of obesity. Mol Metab. 2022;57:101351. PMID: 34626851
  8. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387(3):205-216. PMID: 35658024
  9. Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989-1002. PMID: 33567185
  10. Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023;389(24):2221-2232. PMID: 37952131